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Antiretroviral therapy corrects HIV-1–induced expansion
of CD81CD45RA1CD272CD11abright activated T cells
Li Yin, MD, PhD,a* Carina A. Rodriguez, MD,b* Wei Hou, PhD,c Olivia Potter, MS,d Margaret J. Caplan, BA,b
Maureen M. Goodenow, PhD,a and John W. Sleasman, MDd Gainesville and St Petersburg, FlaBackground: HIV infection decreases thymic output and
induces chronic T-cell activation.
Objective: To examine the reconstitution of naive and activated
T cells.
Methods: Extended immune phenotyping of CD41 and CD81
T-cell subsets was combined with T-cell receptor rearrangement
excision circle (TREC) levels and measures of T-cell receptor
repertoire perturbations in CD81 T-cell subpopulation to
define the global effect of HIV-1 on T-cell dynamics.
Evaluations before and after therapy were performed in HIV-
infected children and compared with those in healthy
individuals.
Results: Ten HIV-infected children and adolescents with a
broad range of pretherapy CD41 T-cell counts were
compared with healthy individuals. Pretherapy late activated
CD81 T cells (CD31CD81CD45RA1CD272CD11abright cells)
were expanded among HIV-infected subjects. Successful
antiretroviral therapy increased the proportion of naive T cells
(CD31CD41CD45RA1CD271CD281 and CD31
CD81CD45RA1CD271CD11adim cells), with a significant
decrease in late activated CD81 T cells. The proportion of
naive CD41 and CD81 T cells significantly predicted log10
TREC copies/106 PBMCs in infected children and healthy
control subjects, with a negative correlation in late activated
CD81 T cells and activated CD41 T cells. Treatment
re-established Gaussian distributions and decreased oligoclonal
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but compared with that seen in healthy children, the proportion
of late activated CD81 T cells remained increased.
Conclusion: HIV infection strikingly shifts the proportion of
naive and late activated CD45RA1CD81 T cells. Homeostasis
within this T-cell population reflects TREC levels and the extent
of T-cell receptor Vb perturbations. (J Allergy Clin Immunol
2008;122:166-72.)
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T cells
HIV-1 infection diminishes cellular immunity by impairing
the capacity of the thymus to produce new T cells and by
inducing a chronic state of T-cell activation.1,2 Studies in HIV-
infected children before and after control of viral replication
with combination antiretroviral therapy have provided the best
insight into the dynamics of thymic output, as measured by using
T-cell receptor rearrangement excision circles (TRECs).3-5 Al-
though blood TREC levels are a function of the production of re-
cent thymic emigrants and the degree of T-cell turnover and
activation,6,7 the extent of cellular activation and thymic output
cannot be assessed with TREC levels alone. Integration of ex-
tended immune phenotyping of T-cell activation and differentia-
tion markers with an assessment of oligoclonal expansion within
the T-cell receptor (TCR) repertoire can provide precise and
global means to measure viral effects on T-cell development
and activation.8,9
Development of multiparameter flow cytometry has greatly
enhanced the ability to investigate T-cell activation and differen-
tiation and to accurately define T-cell phenotypes based on
coexpression of multiple surface markers expressed on the
same cell.10 Recent studies with multiparameter flow cytometry
reveal that CD41 and CD81 T-cell subsets are highly heteroge-
neous with respect to cell-surface phenotype.11,12 In our study
we examined the changes in expression of CD11a and CD27 on
CD31CD81CD45RA1T cells because the combined use of these
markers provides a novel means to differentiate CD81T cells that
are recent thymic emigrants, which are CD271CD11adim, from
late activated effector CD81 T cells, which are CD272
CD11abright.13-16 Furthermore, perturbations within the TCR
Vb repertoire of CD81CD45RA1 T cells correlate with HIV
disease stage and the extent of viral replication.17 In this study
TREC levels, T-cell activation and differentiation phenotypes,
and perturbations within the TCR Vb repertoire were combined
to define the global effect of HIV infection on T-cell dynamics
before and after antiretroviral therapy. Results were compared
with those of a cohort of healthy individuals across age groups
to define the relationship between T-cell phenotypes and TREC
levels.
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METHODS
Subjects
The study population consisted of 10 HIV-infected children and adoles-
cents. Longitudinal blood samples were collected prospectively and cryopre-
served as PBMCs as part of a study of HIV-1 genetic variability.18 The criteria
for selection included subjects who had CD41 T-cell counts that were either
greater or less than 15%. All but 1 subject, who was infected as a neonate
through blood transfusion, were infected through mother-to-child transmis-
sions. All received similar antiretroviral regimens consisting of a protease
inhibitor plus 2 nucleotide reverse transcriptase inhibitors, which fully sup-
pressed viral replication to less than 400 copies/mL over the 96-week obser-
vation period. The pretherapy and 96-week posttherapy samples were
analyzed. In addition, PBMC samples were obtained from 19 children, adoles-
cents, and adults ranging in age from 4 to 80 years with no underlying medical
conditions, recent illnesses, or immunizations. Informed consent was obtained
from each subject according to protocols approved by the Institutional Review
Boards of the University of Florida and All Children’s Hospital.
Assessment of TREC levels in PBMCs
The frequency of signal joining TRECs in PBMCswas quantified bymeans
of real-time quantitative PCR by using primers and a fluorogenic probe, as
described in the Methods section of the Online Repository (available at
www.jacionline.org).7 Data were expressed as TREC copies/106 PBMCs by
usingmean values from triplicate TRECmeasurements and duplicate apolipo-
protein B TaqMan assays.
Measurement of T-cell subsets
T-lymphocyte subsets from PBMCs were stained as outlined in the
Methods section of the Online Repository and analyzed with a multiparameter
LSR 2 flow cytometer (BD Biosciences, San Jose, Calif; http://www.
bdbioscience.com).
Measurement of TCR Vb CDR3 length variation
CD81CD45RA1T lymphocytes were purified from PBMCs, as previously
described.18,19 TCRVbCDR3 size analysis was performed for 21 Vb families
by using a 2-step PCR and analytic methods, as described previously.17
Statistical analysis
Analysis was performed with SAS version 9.1 (SAS Institute, Cary, NC).
Because of the small sample size, the statistical power is low for testing the
distribution of data. Previous studies of HIV-infected cohorts have demon-
strated that T-cell counts and viral load follow logarithmic transformed normal
distribution.20,21 Therefore all variables were log10 transformed for statistical
analysis. Comparisons between pretherapy and posttherapy variables within
HIV-infected children and comparisons between HIV-infected and healthy in-
dividuals were performed by using repeated ANOVA. These comparisons
were performed with an age-matched control group consisting of 7 healthy
subjects (age range, 6-15 years) selected within the 19 healthy subjects. Pear-
son correlation coefficients were used to study the relationship between 2 var-
iables. Regressions with repeated measures were used to determine whether
HIV infection altered the relationship between the proportion of naive or
activated CD41 and CD81 T cells and recent thymic emigrants, as defined
by TREC numbers. For each regression model, TREC level was treated as
the outcome, whereas the proportion of naive CD41 or CD81 or activated
CD41 or CD81 T cells was treated as the continuous covariate, and the pre-
therapy, posttherapy, and healthy groups were the categorical factors.Autocorrelation within each subject was assumed between pretherapy and
posttherapy repeated measures. Three linear regression lines were fitted, one
for each of the pretherapy HIV-infected, posttherapy HIV-infected, and
healthy cohortmeasures. Differences in regression slopes between the prether-
apy, posttherapy, and healthy control groups were tested by using contrasts
based on the regression models. P values of less than .05 were considered sta-
tistically significant.
RESULTS
Characteristics of the study population
Ten HIV-infected children and adolescents in whom antire-
troviral therapy was initiated after infancy were selected to
represent a broad range of pretherapy CD41T-cell counts and dis-
ease stages (Table I). Mean age and length of infection before the
start of antiretroviral therapy was 10.3 6 5.4 years. Pretherapy
CD41 T-cell percentages ranged from 3% to 34% (mean, 16%
6 9%), whereas the mean CD4/CD8 T-cell ratio was 0.35 6
0.33. Baseline viral load ranged from 3.2 to 5.9 (mean, 4.4 6
0.8) log10 HIV-1 RNA copies/mL. All subjects achieved undetect-
able viral loads within 16 (median 9) weeks after the start of treat-
ment and maintained suppression at undetectable levels through
96 weeks.
Thymic output is directly related to CD41 T-cell
counts before and after therapy
Before therapy, the HIV-infected children had TREC levels that
varied from 2.9 to 4.6 (mean, 3.9 6 0.6) log10 TREC copies/10
6
PBMCs. TREC levels among HIV-infected children and adoles-
cents were compared with TREC levels for age among a group
of 19 healthy individuals (Fig 1). Among all 19 healthy subjects,
there was a negative correlation between age and TREC levels
(r 5 20.89, P < .001). Among HIV-infected subjects, 7 had
TREC levels that were within the 95% CI for healthy subjects
controlled for age, whereas 3 (nos. P1, P3, and P5) had pretherapy
TREC levels that were less than the lower bound of the 95% CI.
After therapy and control of viremia, all subjects had TREC levels
within the 95% CI for healthy subjects.
Pretherapy TREC levels correlated directly with CD41 T-cell
absolute numbers (r 5 0.83, P 5 .003) and percentages (r 5
0.89, P 5 .001), as well as the CD4/CD8 T-cell ratio (r 5 0.83,
P5 .003). Overall, control of viral replication after antiretroviral
therapy resulted in a significant increase in TREC levels to amean
of 4.46 0.3 log10 copies/10
6 PBMCs (P5 .012). Increased num-
bers of TRECs were accompanied by increases in CD4 percent-
ages (mean, 33% 6 11%; P < .001) and absolute CD41 T cells
(from 3756 293 to 8316 460 cells/mL, P5 .003) and improved
CD4/CD8 ratio (0.996 0.63, P<.001). In contrast, changes in ab-
solute CD81 T cells (mean, 11096 454 cells/mL before therapy
to 9756 521 cells/mL after therapy) failed to achieve significance
(P5 .307) and showed no relationship to changes in TREC levels
(P 5 .702). Posttherapy increase in TREC levels directly corre-
lated with increase in percentages and counts of CD41 T cells
and CD4/CD8 ratio (r 5 0.89, P 5 .001; r 5 0.92, P < .001;
and r 5 0.88, P 5 0.001; respectively).
Changes in T-cell differentiation and activation
after therapy
As expected, therapy resulted in significantly increased per-
centages of naive CD41 T cells (CD31 CD41CD45RA1
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Patient no. CDCy Age (y)
CD4 (%) CD8 (%) CD4/CD8 VLz log10
Naive/activated
CD4§ (%)
Naive/
activated
CD8k (%)
TREC{
log10
copies/106
PBMCs
Pre Post Pre Post Pre Post Pre Before Post Pre Post Pre Post
1 C 6.2 3 24 60 37 0.05 0.65 5.9 13/74 77/14 33/67 86/14 2.9 4.8
2 C 17.4 6 21 45 34 0.13 0.62 4.4 48/43 50/30 48/52 84/16 3.6 4.0
3* C 16.8 9 42 64 29 0.14 1.45 5.1 15/48 60/11 27/73 85/15 3.2 4.6
4 A 16.7 13 27 69 51 0.19 0.53 3.7 53/42 50/30 25/75 61/39 4.0 4.4
5 B 6.7 14 16 57 56 0.25 0.29 4.2 50/36 50/40 40/60 59/41 3.8 4.0
6 B 9.9 17 38 50 33 0.34 1.15 4.5 62/09 55/06 73/27 90/10 4.4 4.6
7 B 5.1 22 42 55 40 0.40 1.05 4.3 62/19 64/21 92/08 82/18 4.6 4.6
8 A 5.5 23 34 48 35 0.48 0.97 4.0 72/08 82/06 31/69 58/42 4.3 4.2
9 B 14.5 23 36 66 55 0.35 0.65 4.9 42/15 59/15 73/27 95/05 4.3 4.5
10 B 4.3 34 50 28 20 1.21 2.50 3.2 71/22 79/17 60/40 84/16 4.3 4.5
CDC, Centers for Disease Control and Prevention; VL, viral load; Pre, pretherapy; Post, posttherapy.
*Infected perinatally by means of blood transfusion; all others infected by mother-to-child transmission.
Disease stage.
Log10 HIV-1 RNA copies/mL.
§Naive CD41 T lymphocytes (CD31CD41CD45RA1CD271CD281); activated CD41 T lymphocytes (CD31CD41CD45RO1CD272CD282).
kNaive CD81 T lymphocytes (CD31CD81CD45RA1CD271CD11adim); activated CD81 T lymphocytes (CD31CD81CD45RA1CD272CD11abright).
{TCR rearrangement excision circle.CD271CD281 cells), from 49% 6 21% to 63% 6 12% (P 5
.044). The proportion of activated CD41 T cells (CD31CD41
CD45RO1CD272CD282 cells) decreased from 32% 6 21% to
19% 6 11% (P 5 .025). Numbers of naive and activated CD41
T cells among HIV-1–infected children after successful therapy
were similar to the levels found among healthy children of a sim-
ilar age (12.0 6 0.3 years; P 5 .359 and .869, respectively).
Because there was no change in the absolute numbers
of CD81 T cells, we evaluated the proportion of naive
(CD31CD81CD45RA1CD271CD11adim), early activated (CD31
CD81CD45RO1CD272CD11abright), and late activated (CD31
CD81CD45RA1CD272CD11abright) populations8 to determine
whether control of viral replication resulted in shifts within the
CD81 T-cell subsets. Nearly all CD31CD81CD45RO1 T cells
were CD272 and expressed high levels of CD11a, the phenotype
of an early activated subset (data not shown). In contrast,
CD31CD81CD45RA1T cells included 2 subsets, naive and acti-
vated, based on the combined expression of CD27 and CD11a
FIG 1. Correlation between age and log10 TREC copies/10
6 PBMCs. The
log10 TREC copies/10
6 PBMCs (y-axis) and age (x-axis) were compared in
healthy control subjects (open circles) and HIV-infected pretherapy (open
triangles) and posttherapy (filled triangles) subjects. The mean TREC
copies/106 PBMCs (solid line) and 95% CIs (dashed line) for healthy
subjects are shown.(Fig 2, A). Within the CD31CD81CD45RA1 T cells shown for
a healthy child, the naive CD271CD11adim cells predominated,
whereas in the HIV-infected child less than 30% are naive, and
the majority are activated and express CD272CD11abright (Fig
2,B). Treatment of this individual changed the proportion of naive
to activated CD31CD81CD45RA1 T cells to levels similar to
those seen in the healthy child.
Untreated HIV-infected children had levels of naive CD81
lymphocytes (mean, 50% 6 23%) that were significantly lower
than those of age-matched healthy children (79% 6 8%, P 5
.007, see Table E1 in the Online Repository at www.jacionli-
ne.org). Similarly, among infected children, late activated T cells
were at significantly higher levels than in healthy children (mean,
50%6 23% and 13%6 8%, respectively;P5.001). Therapy sig-
nificantly decreased the proportion of late activated CD81 T cells
to levels that were similar to those in healthy children (22% 6
14% vs 13% 6 8%, P 5 .118). The decrease in late activated
CD81CD45RA1T cells reflected an increase in the naive subset
from a mean of 50%6 23% to 78%6 14% (P < .001). The pro-
portion of naive CD81 T cells among treated children was indis-
tinguishable from the levels among healthy children (mean, 79%
6 8%, P5 .880). Overall, there was a shift with CD81CD45RA1
T cells after therapy from a preponderance of activated cells to a
preponderance of naive cells. However, when compared with
healthy children, the posttherapy CD4/CD8 ratio remained low
(0.99 6 0.63 vs 2.3 6 0.8, P 5 .009), and the proportion of acti-
vated CD81T cells within total CD31T cells was higher than that
seen in healthy children (4.1 6 2.5 vs 2.2 6 2.0, P 5 .033).
Relationship between thymic output and CD41 or
CD81 T-cell subpopulations
The relationship between TREC levels and the proportion of
naive CD41 and CD81 T cells was evaluated by using regression
analysis with repeated measures to determine whether it is dif-
ferent between healthy and pretherapy and posttherapy HIV-in-
fected individuals. Three regression lines were fitted for those
groups. The proportion of naive CD81 T cells (CD31CD81
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YIN ET AL 169FIG 2. Naive and activated CD81 T-cell populations. A, Representative analysis of CD81 cells within CD31
T cells further gated to CD45RA (center panel) and enumerated as naive (CD31CD81CD45RA1CD271
CD11adim) or activated (CD31CD81CD45RA1CD272CD11abright) T cells. B, Representative histogram of
CD11adim and CD11abright CD31CD81CD45RA1 T cells in healthy and HIV-infected (pretherapy and postther-
apy) subjects. Fl, Fluorescence intensity.CD45RA1CD271CD11adim cells) significantly predicted log10
TREC copies/106 PBMCs in pretherapy and healthy control sub-
jects (b5 28.64, P5 .010 and b5 14.84, P5 .043, respectively)
but not in posttherapy subjects (b 5 9.79, P 5 .498; Fig 3, A).
The proportion of late activated CD81 T cells (CD31
CD81CD45RA1CD272CD11abright) significantly predicted
log10 TREC copies/10
6 PBMCs in pretherapy (b 5 228.66,
P 5 .010), but not in posttherapy and healthy control (b 5
29.41, P 5 .516 and b 5 211.68, P 5 .092, respectively), sub-
jects (Fig 3, B). The proportion of naive CD41 T cells (CD31
CD41CD45RA1CD271CD281 cells) significantly predicted
log10 TREC copies/10
6 PBMCs in pretherapy, posttherapy, and
healthy control subjects (b 5 30.31, P 5 .006; b 5 36.36, P 5
.043; and b5 12.30, P5 .047; respectively; Fig 3, C). Similarly,
the proportion of activated CD41 T cells (CD31CD41
CD45RO1CD272CD282 cells) significantly predicted log10
TREC copies/106 PBMCs in pretherapy, posttherapy, and healthy
control subjects (b 5 230.64, P < .001; b 5 232.22, P 5 .005;
and b 5 215.26, P 5 0.018; respectively; Fig 3, D). However,
the regression slopes between TREC levels and naive and acti-
vated CD81 and CD41 T cells were not significantly different
among healthy control subjects and HIV-infected individuals
before and after antiretroviral therapy.
Changes in the TCR CDR3 Vb repertoire, TREC
levels, and CD81CD45RA1 T-cell subsets after
therapy
CDR3 length variations within individual TCR Vb families
were evaluated by spectratyping to determine whether therapy
modulated the TCRVb repertoire within CD81CD45RA1T cellssimilar to the changes in TREC levels. Changes in the TCR Vb
repertoire are illustrated for 2 representative subjects (Fig 4). Sub-
ject P2 had pretherapy TREC levels of 3.6 log10 copies/mL and
oligoclonal expansions in Vb1, Vb6, Vb11, Vb12, Vb17, and
Vb20. With treatment, the TCRVb repertoire reverted to a Gaus-
sian distribution, and TREC levels increased to 4.0 log10 copies/
mL. Subject P6 had fewer pretherapy perturbations (Vb3 and
Vb15) but higher pretherapy TREC levels (4.4 log10 copies/
mL) that also normalized with treatment.
The number of perturbed Vb families within CD81CD45RA1
T cells decreased significantly after therapy among 4 subjects
(P5 .040). Therapy-associated increases in TREC levels were as-
sociatedwith a decrease in the number of perturbations in the TCR
Vb repertoire of CD81CD45RA1 T cells (Fig 5, A). Similarly,
therapy-induced decreases in TCRVb perturbations were associ-
ated with increases in naive CD81 T cells (Fig 5, B) and decreases
in the proportion of activated CD81T cells (Fig 5,C). Therewas a
clear trend toward normalization of the TCR Vb repertoire that
positively correlated with increases in TREC levels and naive
CD81 T cells (r 5 20.82, P 5 .090; r 5 20.79, P 5 .120) and
negatively correlated with the proportions of activated
CD81CD45RA1T cells (r 5 0.84, P 5 .08).
DISCUSSION
Multiple aspects of the treatment-induced changes in the
dynamics of T-cell activation and differentiation have been
examined in studies involving HIV-infected children.3-5,17,22
However, few have integrated changes in T-cell differentiation
and activation using multiparameter flow cytometric analysis
and compared the findings with assessments of TREC levels
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fore and after therapy. TCR CDR3 amino acid (aa) length distributions (x-axis) for selected Vb families of
2 representative subjects (P2 and P6) are compared before (upper panel) and after (lower panel) therapy.
Fluorescence intensity (Fl) is shown on the y-axis.
FIG 3. Relationship between thymic output and CD41 and CD81 T-cell subsets. TREC copies/106 PBMCs
(x-axis) compared with percentage of naive CD81 and CD41 T cells (A and C) and activated CD81 and CD41
T cells (B and D, y-axis) are shown. Healthy subjects (open circles) and HIV-infected pretherapy (open
triangles) and posttherapy (solid triangles) subjects are shown. Regression lines show healthy (dotted
line), pretherapy infected (dashed line), and posttherapy infected (dashed and dotted line) subjects.and TCR CDR3 length variation. Examining T-cell reconstitution
in HIV-infected children provides an opportunity to observe the
effects of shifts within thymic output and T-cell activation be-
cause thymic function is more intact in children when compared
with adults. Our results also combine these multiple measures to
define relationships between HIV-infected and healthy individ-
uals. Similar to other studies of immune reconstitution in HIV-in-
fected children, we found positive correlations between TREC
levels and increases in CD41 T-cell absolute counts, percentages,
and the proportion of naive CD41 T cells.3,23,24 The extent to
whichHIV-infected childrenwho delayed therapywere able to re-
constitute thymic output was surprising because the posttherapy
TREC levels and proportions of naive T cells were equivalentto those seen in age-matched healthy children. Previous studies
have shown reconstitution of functional immunity, as measured
by response to immunizations, improved growth parameters,
and decreases in HIV-related clinical conditions among children
who reconstitute CD41 T cells.25
Although total CD81 T-cell numbers did not change signifi-
cantly after treatment among the HIV-infected cohort, there
were striking shifts in the proportion of naive and late activated
CD81CD45RA1 T cells. Control of viral replication resulted in
dramatic increases in both naive CD41 and CD81 T cells, achiev-
ing levels similar to those seen in age-matched healthy children.
However, HIV-infected children demonstrated an unexpected in-
crease of late activated CD81 T cells, with more than half of these
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T cells. Number of TCR Vb families with oligoclonal expansions (y-axis) compared with TREC copies/106
PBMCs (A) and percentage of naive (B) and activated (C) CD81 T cells (x-axis) are shown. Changes are
shown among 4 HIV-infected subjects before (open triangles) and after (solid triangles) therapy.chronically infected children showing greater than 50% of their
CD81CD45RA1 T cells expressing CD11abright. HIV-1 skews
T-cell maturation of CD81 T cells and alters the normal propor-
tions of naive, early activated, and memory effector T cells.8,26
Expansion of late activated T cells to this extent has not been pre-
viously reported in children and indicates a potentially novel
mechanism of virally induced perturbations of T-cell dynamics.
Control of viral replication resulted in a significant decrease in
the late activated subsets. However, as a percentage of total
CD31 T cells, late activated CD81 T cell numbers remained
higher than in healthy children. This finding, in conjunction
with persistent inversion of the CD4/CD8 ratio, indicates ongoing
T-cell activation, even though viral replication is fully suppressed.
Our results indicate that CD45RA1 is an unreliable marker of
naive CD81 T cells. Its composition is highly heterogeneous,
composed of naive and late activated cells.16 Previous studies lim-
ited to the use of 3- or 4-color flow cytometric analysis of CD81
T-cell subsets might have led to erroneous conclusions of reten-
tion of naive CD81 CD45RA1 T cells in children and adoles-
cents.27 The application of multiparameter flow cytometry
provides a more accurate means to assess CD81 T-cell dynamics.
One of the goals of this study was to examine the relationships
between TREC levels and CD41 and CD81 T-cell subsets in
both HIV-infected and healthy cohorts. As expected, the propor-
tion of naive CD41 and CD81 cells was highly predictive of
TREC levels, with regression slopes that were not significantly
different. The negative correlations between TREC levels and
activated CD41 and CD81 T cells, most evident in untreated
HIV-infected children, is a novel observation indicating that ac-
tivated T cells predict low TREC levels. These results show that
total TREC levels within PBMCs reflect both thymic output and
the level of activated T cells. Expanded flow cytometric analysis
to assess both aspects of T-cell homeostasis is more valuable
than simple 3-color evaluations of lymphocyte subsets. Further-
more, the extended analysis with 8-color cytometry can effec-
tively be performed by using small numbers of lymphocytes.10
The extent of viral replication and CD41 T-cell depletion cor-
relates with oligoclonal expansion of the TCR Vb repertoire
within CD81CD45RA1 T cells. TCR perturbations resolve
when HIV-1 replication is controlled.17 Our study shows that
posttherapy decreases in late activated CD81CD45RA1 T cells
directly correlate with the normalization of the TCR repertoire
within CD81CD45RA1T cells. Successful antiretroviral therapy
also re-establishes the proportion of naive CD81 T cells and
returns the TCR repertoire to a Gaussian distribution. Chronicviral infection leads to increases in the magnitude of oligoclonal
expansion of virus-specific cytotoxic T cells that express
CD11abright.28 An extension of our study would be to examine
the distribution and clonality of HIV-specific cytotoxic T cells
within CD81CD45RA1 lymphocytes.
Most studies of immune reconstitution in HIV-infected chil-
dren have focused on changes within CD41 T cells after therapy.
Few have systematically studied CD81 T cells by using extended
T-cell phenotyping. However, the studies that have been done
show high proportions of activated CD81 T cells and expansions
within the TCRVb repertoire, in some cases expansions that are
as much as 70% of the activated CD81 T-cell population.29,30 Our
study is unique in its focus on the dramatic shift in proportions of
naive and late activated T cells, analysis not feasible before the
application of multiparameter flow cytometry. Measurements of
TREC levels within total PBMCs cannot differentiate between
dilutions because of cellular proliferation or decreases in thymic
output, limiting its clinical monitoring utility in HIV-infected
individuals. However, TREC measurement can be used as a
high-throughput means to measure total T-cell numbers. It can
be performed using small volumes of blood, and unlike extended
flow cytometric analysis, molecular assessment of TREC levels is
inexpensive, does not require refrigeration for transport, and does
not involve extensive processing at the clinical site.31,32 Analysis
of TREC levels on dried filter paper spots could be easily applied
as a simple means to monitor T-cell homeostasis in HIV-infected
children in resource-poor settings.
Clinical implications: Multiparameter flow cytometry accu-
rately measures thymic output and virus-induced T-cell expan-
sions within HIV-infected children.
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Real-time PCR for measurement of thymic output
DNAwas extracted from cryopreserved PBMCs. Cells were lysed in lysis
buffer containing 100 mg/mL proteinase K (Roche Diagnostics, Indianapolis,
Ind) at a concentration of 106 cells/50 mL for 3 hours at 568C and then for 30
minutes at 958C to inactivate the proteinase K. Five microliters of cell lysate
equivalent to 100,000 cells was used as a template for PCR amplification. PCR
reactions were performed in 25 mL containing 2.03 TaqMan Universal PCR
MasterMix (PEApplied Biosystems, Foster City, Calif; 12.5mmol/L forward,
59-CACATCCCTTTCAACCATGCT-39; 12mmol/L reverse, 59-GCCAGC
TGC AGG GTT TAG G-39 primers) and 25 mmol/L of the fluorogenic probe
(59-ACA CCT CTG GTT TTT GTA AAG GTG CCC ACT-39) conjugated
with the fluorophores 6-carboxyfluorescein at the 59 end and 6-carboxytetra-
methilrhodamine at the 39 end. ApoB quantification was performed in parallel
PCR reactions by using the following primers and probe: forward primer, 59-
TGAA GGT GGA GGA CAT TCC TCTA-39; reverse primer, 59-CTG GAA
TTG CGATTT CTGGTA A-39; fluorogenic probe, 59- CGAGAATCACCC
TGCCAGACTTCCGT-39. Thesewere conjugated with the fluorophore VIC
at the 59 end and 6-carboxytetramethilrhodamine at the 39 end. The thermal
cycling conditions were as follows: 2 minutes at 508C, 10 minutes at 958C,and 40 cycles each of 958C for 30 seconds and 608C for 1 minute. A spectro-
fluorometric thermal cycler (ABI PRISM 7900 Sequence Detector, PE
Applied Biosystems) was used for amplification and detection, and ABI
sequence detection system software was used for generation of a standard
curve and quantification of TREC levels. Positive controls with DNA from
cord blood and Jurkat cells and negative nontemplate controls were included
in every plate run.
Definition of T-cell subsets
PBMCs from study subject were incubated with the relevant antibodies for
30 minutes in PBS buffer containing 2% FCS and 0.1% sodium azide. Cells
were then washed twice, fixed with 1% paraformaldehyde, and analyzed with
a multiparameter LSR 2 flow cytometer (BD Biosciences). CD41 T-cell
subsets were defined as follows: naive CD41 T cells, CD31CD41
CD45RA1CD271CD281; activated CD41 T cells, CD31CD41CD45RO1
CD272CD282. CD81 T-cell subsets were defined as follows: naive,
CD31CD81CD45RA1CD271CD11adim; early activated, CD31CD81
CD45RO1CD272CD11abright; and late activated, CD31CD81CD45RA1
CD272CD11abright.
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Variables
HIV-infected children (n 5 10)
Healthy children# (n 5 7)Pre Post P value* P valuey P valuez
CD4
% (CD3)§ 16.4 6 9.4 33.0 6 10.7 56.0 6 12.5 <.001 <.001 .021
Naive % (CD4)k 48.7 6 20.7 62.7 6 12.4 74.2 6 6.4 .044 .035 .359
Activated (CD4)k 31.6 6 20.8 19.0 6 11.4 17.9 6 6.6 .025 .212 .869
Naive % (CD3)§ 9.3 6 7.3 21.2 6 9.3 44.3 6 9.7 .001 .001 .063
Activated (CD3)§ 3.8 6 1.9 5.6 6 2.5 10.7 6 4.0 <.001 .001 .017
CD8
% (CD3)§ 54.2 6 12.1 39.0 6 11.7 27.5 6 7.3 <.001 <.001 .028
Naive % (CD8CD45RA){ 50.2 6 23.2 78.4 6 13.7 79.4 6 8.0 <.001 .007 .880
Activated (CD8CD45RA){ 49.8 6 23.2 21.6 6 13.7 12.5 6 7.5 .003 .001 .118
Naive % (CD3)§ 10.8 6 7.7 16.7 6 7.8 12.2 6 4.2 .008 .323 .279
Activated (CD3)§ 10.8 6 8.5 4.1 6 2.5 2.2 6 2.0 .010 .001 .033
CD4/CD8 0.35 6 0.33 0.99 6 0.63 2.3 6 0.8 <.001 <.001 .009
Pre, Pretherapy; Post, posttherapy.
*P < .05, comparison between pretherapy and posttherapy variables within HIV-infected subjects.
P < .05, comparison of HIV-infected pretherapy variables with age-matched healthy control variables.
P < .05, comparison of HIV-infected posttherapy variables with age-matched healthy control variables.
§As percentage gated on CD31 T cells.
kAs percentage gated on CD41 T cells.
{As percentage gated on CD81CD45RA1 T cells.
#Age matched.
